Celldex Therapeutics (CLDX) Retained Earnings (2010 - 2026)

Celldex Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 29.32% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (down 29.32% YoY), while the FY2025 annual figure was $3.6 million, up 100.23% from the prior year.
• Retained Earnings for Q1 2026 stood at $2.5 million, down from $3.6 million in the prior quarter.
• The five-year high for Retained Earnings was $5.3 million in Q3 2024, with the low at -$1.7 billion in Q3 2025.
• The 5-year median for Retained Earnings is -$417000.0 (2022), against an average of -$679.6 million.
• Peak annual rise in Retained Earnings reached 1795.54% in 2023, while the deepest fall reached 315438.37% in 2023.
• Celldex Therapeutics' Retained Earnings stood at -$1.3 billion in 2022, then surged by 100.26% to $3.3 million in 2023, then tumbled by 47114.03% to -$1.6 billion in 2024, then jumped by 100.23% to $3.6 million in 2025, then plunged by 30.45% to $2.5 million in 2026.
• Business Quant data shows CLDX's Retained Earnings at $2.5 million in Q1 2026, $3.6 million in Q4 2025, and -$1.7 billion in Q3 2025.